Affinage

NPAS3

Neuronal PAS domain-containing protein 3 · UniProt Q8IXF0

Length
933 aa
Mass
100.8 kDa
Annotated
2026-06-10
34 papers in source corpus 17 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NPAS3 is a bHLH-PAS transcription factor that governs neurodevelopmental and metabolic gene programs by obligatorily heterodimerizing with ARNT to bind DNA and regulate target genes (PMID:27782878, PMID:30509165). Crystal structures of multi-domain NPAS3-ARNT-DNA complexes establish that productive DNA binding requires the heterodimer and reveal four putative ligand-binding pockets, defining NPAS3 as a candidate multi-ligand-sensing factor (PMID:27782878); dimerization occurs through both the bHLH and PAS domains, while a C-terminal transactivation domain drives gene activation (PMID:30509165). Through this complex NPAS3 activates targets including VGF and Shh and represses Spry2 and multiple glycolysis genes, coupling neurodevelopmental transcription to glucose metabolism (PMID:30509165, PMID:21709683, PMID:19581591). NPAS3 is required for lung branching morphogenesis via FGF/SHH signaling, with exogenous FGF10 rescuing the Npas3-null defect (PMID:19581591), and it controls cortical development by regulating progenitor-to-neuron transitions, radial migration, and astrogenesis, where ChIP-seq defines targets in brain development and synapse organization (PMID:36044858, PMID:36313621). Its activity is constrained post-transcriptionally by miR-17 binding to the 3' UTR (PMID:22228753) and post-translationally by AEBP1-mediated cytoplasmic sequestration, which blocks NPAS3 from activating Lipa and promotes lipid and amyloid pathology in astrocytes (PMID:41880326). Disease-associated truncation variants abolish transcriptional activity by preventing ARNT2 heterodimerization (PMID:33758288), and the schizophrenia-segregating V304I mutation, like oxidative stress, drives NPAS3 into insoluble aggregates that deplete functional soluble protein (PMID:27867938, PMID:34834422).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2004 Medium

    Established that NPAS3 operates within inhibitory interneurons to govern a specific molecular program, moving it from an orphan factor to a defined neuronal regulator.

    Evidence Immunohistochemistry plus NPAS1/NPAS3 double-knockout mice showing reduced reelin expression and behavioral deficits

    PMID:15347806

    Open questions at the time
    • Does not show direct binding of NPAS3 to the reelin gene
    • Confounded by simultaneous loss of NPAS1
  2. 2005 Medium

    Defined the in vivo developmental consequence of NPAS3 loss, linking it to brain morphogenesis and postsynaptic signaling.

    Evidence Npas3 knockout mouse with neuroanatomical defects, altered PSD-95, and neurotransmitter pharmacology

    PMID:16190882

    Open questions at the time
    • Phenotypes are downstream and do not identify direct transcriptional targets
    • Mechanism connecting NPAS3 to PSD-95 unresolved
  3. 2009 High

    Identified direct transcriptional targets of NPAS3 and a tissue role outside the brain, showing it activates Shh and represses Spry2 to drive FGF/SHH-dependent lung branching.

    Evidence Npas3-null mouse with reduced Shh/Fgf9/Fgf10/Bmp4 and increased Spry2, promoter reporter assays, and FGF10 rescue

    PMID:19581591

    Open questions at the time
    • Did not resolve the dimerization partner required for these promoter activities
    • Direct E-box occupancy in vivo not mapped
  4. 2011 High

    Connected NPAS3 transcription to metabolism and localized it to the maturation phase of adult neurogenesis, revealing a dual neurodevelopmental and metabolic role.

    Evidence Microarray of NPAS3-overexpressing HEK293 cells (VGF induction, glycolysis repression), KO mouse brain metabolomics, and subgranular-zone immunofluorescence

    PMID:21709683

    Open questions at the time
    • Metabolic gene repression not shown to be via direct promoter binding
    • Mechanism linking NPAS3 to NAD+/Krebs intermediates unresolved
  5. 2012 Medium

    Explained the post-transcriptional uncoupling of NPAS3 mRNA and protein during cortical development by identifying miR-17 control of its 3' UTR.

    Evidence Luciferase 3' UTR reporter assays plus expression profiling in postmortem human cortex

    PMID:22228753

    Open questions at the time
    • Does not establish whether miR-17 regulation alters NPAS3 transcriptional output
    • Single miRNA examined
  6. 2016 High

    Solved the structural and mechanistic basis of NPAS3 DNA binding, proving obligate ARNT heterodimerization and revealing candidate ligand pockets.

    Evidence X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes

    PMID:27782878

    Open questions at the time
    • Endogenous ligands for the four pockets unidentified
    • Does not address tissue-specific cofactor selection
  7. 2016 Medium

    Refined the VGF activation mechanism, showing NPAS3 acts in part through NF-κB signaling rather than solely direct E-box binding, and links VGF to proliferation.

    Evidence Reporter assays with mutated E-box/κB sites, NF-κB western blotting, and VGF-knockdown proliferation assays in PC12 cells

    PMID:27877109

    Open questions at the time
    • Direct vs. indirect NF-κB induction not distinguished
    • Single cell-line system
  8. 2016 Medium

    Introduced protein aggregation as a disease mechanism, showing a schizophrenia-segregating mutation increases NPAS3 insolubility and alters its activity.

    Evidence Wild-type vs. V304I expression in bacterial and mammalian systems, solubility fractionation, and reporter assays

    PMID:27867938

    Open questions at the time
    • Causality from a single small family
    • Structural basis of aggregation not defined
  9. 2018 High

    Mapped the NPAS3-ARNT interaction to both bHLH and PAS domains and localized the transactivation function and direct VGF/TXNIP promoter binding.

    Evidence Reciprocal Co-IP, domain truncation, reporter and promoter binding assays in human cells

    PMID:30509165

    Open questions at the time
    • Does not establish in vivo occupancy at these promoters
    • Regulation of TXNIP physiologic context unexplored
  10. 2021 Medium

    Established loss-of-function disease variants act by abolishing heterodimerization, tying clinical truncations directly to the dimerization requirement.

    Evidence Reporter transcriptional assays and Co-IP with ARNT2 for clinical truncation variants

    PMID:33758288

    Open questions at the time
    • Patient phenotype-to-molecular-defect correlation limited
    • ARNT vs. ARNT2 partner preference in vivo unresolved
  11. 2021 Medium

    Generalized NPAS3 aggregation beyond a single mutation, implicating oxidative stress as the dominant driver in human cortex.

    Evidence Insoluble-fraction purification from postmortem human insular cortex and oxidative-stress induction in neuroblastoma cells

    PMID:34834422

    Open questions at the time
    • Functional consequence of widespread aggregation on neuronal physiology unmeasured
    • Trigger of oxidative-stress-driven aggregation in vivo unknown
  12. 2022 High

    Defined a cell-autonomous role in astrogenesis with genome-wide target mapping, showing NPAS3 in astrocytes is needed for synapse organization and behavior.

    Evidence Npas3 KO single-cell RNA-seq, astrocyte ChIP-seq, astrocyte-specific in vivo knockdown, and neuron-astrocyte co-culture

    PMID:36044858

    Open questions at the time
    • Individual functional targets among ChIP-seq peaks not validated
    • Dependence on ARNT partner in astrocytes not tested
  13. 2022 Medium

    Showed NPAS3 controls the progenitor-to-neuron transition, regulating proliferation, fate, and radial migration in developing cortex.

    Evidence In utero knockdown in cortical VZ progenitors with lamination and progenitor-marker analysis

    PMID:36313621

    Open questions at the time
    • Direct transcriptional targets in progenitors not identified
    • Single primary method
  14. 2020 Medium

    Placed NPAS3 downstream of miR-122 in vascular biology, extending its role to endothelial-to-mesenchymal transition and atherosclerosis.

    Evidence miR-122 mimic/inhibitor with NPAS3 siRNA epistasis in endothelial cells and ApoE-/- mouse experiments

    PMID:33278397

    Open questions at the time
    • Direct miR-122 binding to NPAS3 transcript versus indirect effect not fully resolved
    • Transcriptional targets mediating EndMT unidentified
  15. 2023 Medium

    Provided pharmacological proof that disrupting the NPAS3-ARNT interface is feasible, identifying ARNT Cys336 as a covalent targeting site.

    Evidence Biochemical heterodimer-formation assay and cellular reporter assays with a covalent 5-nitrothiazole-2-sulfydryl compound

    PMID:37352720

    Open questions at the time
    • Selectivity over other ARNT-dependent dimers untested
    • In vivo efficacy not demonstrated
  16. 2026 Medium

    Revealed post-translational control of NPAS3 by cytoplasmic sequestration, linking AEBP1-blocked LIPA activation to astrocyte lipid handling and Alzheimer's pathology.

    Evidence Astrocyte-specific AEBP1 knockdown/overexpression in 5xFAD mice, transcriptomics/metabolomics, LIPA promoter binding, and localization assays

    PMID:41880326

    Open questions at the time
    • Direct physical AEBP1-NPAS3 interaction interface not mapped
    • Single disease model

Open questions

Synthesis pass · forward-looking unresolved questions
  • The endogenous ligands occupying the four NPAS3-ARNT pockets and how ligand or partner choice (ARNT vs ARNT2) selects target programs across neurons, astrocytes, lung, and endothelium remain unknown.
  • No identified physiological ligand for the structural pockets
  • Determinants of cell-type-specific target selection unresolved
  • Relationship between aggregation, sequestration, and transcriptional output not unified mechanistically

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003677 DNA binding 3
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 1
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1266738 Developmental Biology 3
Partners
AEBP1ARNTARNT2
Complex memberships
NPAS3-ARNT heterodimer

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 Crystal structures of multi-domain NPAS3-ARNT-DNA complexes reveal that NPAS3 must heterodimerize with ARNT to form functional transcription complexes capable of DNA binding and gene regulation, and that the complex contains four putative ligand-binding pockets, implicating NPAS3 as a multi-ligand-binding transcription factor. X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes eLife High 27782878
2018 NPAS3 directly interacts with ARNT through both bHLH and PAS dimerization domains in human cells; the C-terminus of NPAS3 contains a functional transactivation domain; and the NPAS3::ARNT heterodimer directly binds the proximal promoters of VGF and TXNIP to regulate their expression. Co-immunoprecipitation, reporter gene assays, promoter binding assays, domain deletion/truncation analysis in human cells BMC molecular biology High 30509165
2011 NPAS3 overexpression in HEK293 cells upregulates VGF as its most highly induced transcriptional target, and represses multiple glycolysis genes; knockout mouse brain tissue shows altered levels of NAD+, glycolysis metabolites (dihydroxyacetone phosphate, fructose-1,6-bisphosphate), pentose phosphate pathway components, and Krebs cycle intermediates (succinate, α-ketoglutarate), confirming NPAS3's dual role in neurodevelopmental gene regulation and glucose metabolism. Microarray transcriptomics of NPAS3-overexpressing HEK293 cells; high-resolution mass spectrometry metabolomics of Npas3 KO vs. wild-type mouse brain tissue; immunofluorescence localization Molecular psychiatry High 21709683
2016 NPAS3 regulates VGF expression through the NF-κB signaling pathway rather than solely by direct E-box binding; a κB site within the VGF promoter mediates NPAS3-induced VGF activation, and ectopic NPAS3 expression increases NF-κB (P65) levels. NPAS3-driven cell proliferation can be blocked by VGF knockdown. Reporter assays with mutated E-box and κB sites in VGF promoter; western blotting for NF-κB; VGF knockdown proliferation assays in PC12 cells Frontiers in molecular neuroscience Medium 27877109
2009 NPAS3 is a functional homolog of Drosophila Trachealess and is required for lung branching morphogenesis; in Npas3-null mice, Shh, Fgf9, Fgf10, and Bmp4 mRNAs are decreased and Spry2 is increased. In promoter reporter assays, NPAS3 directly upregulates Shh transcription and represses Spry2 transcription. Exogenous FGF10 rescues branching morphogenesis in Npas3-null lungs. Npas3-null mouse characterization; promoter reporter assays; exogenous FGF10 rescue experiment; quantitative mRNA analysis Proceedings of the National Academy of Sciences of the United States of America High 19581591
2004 NPAS3 is expressed in inhibitory interneurons in the brain, and NPAS3-deficient mice show a distinct reduction in reelin expression, indicating that NPAS3 (together with NPAS1) controls a regulatory program in inhibitory interneurons that governs reelin production. Immunohistochemical staining; NPAS1/NPAS3 double-knockout mouse characterization; behavioral testing (prepulse inhibition, locomotor activity, social recognition) Proceedings of the National Academy of Sciences of the United States of America Medium 15347806
2005 Npas3-null mice display developmental brain abnormalities (reduced anterior hippocampus, corpus callosum hypoplasia, enlarged ventricles) and altered cortical PSD-95 expression, indicating that NPAS3 controls normal brain development and postsynaptic signaling pathways involving glutamate, dopamine, and serotonin neurotransmission. Npas3 knockout mouse generation and characterization; behavioral testing; pharmacological probing of neurotransmitter systems; western blotting for PSD-95 The European journal of neuroscience Medium 16190882
2011 NPAS3 immunoreactivity is localized to the hippocampal subgranular zone (site of adult neurogenesis) in maturing but not proliferating neuronal precursor cells, indicating a role for NPAS3 in the maturation phase of adult hippocampal neurogenesis. Immunofluorescence localization in mouse brain; combined with microarray and metabolomics in the same study Molecular psychiatry Medium 21709683
2016 The V304I mutation in NPAS3, segregating with schizophrenia in a small family, increases NPAS3 protein aggregation propensity in both bacterial and mammalian expression systems, reduces soluble endogenous NPAS3, increases insoluble endogenous NPAS3, and alters its transcriptional activity. Expression of wild-type vs. V304I NPAS3 in bacterial and mammalian systems; soluble/insoluble fractionation; western blotting; transcriptional reporter assays Molecular neuropsychiatry Medium 27867938
2021 Loss-of-function truncation variants of NPAS3 abolish transcriptional activity when partnered with ARNT2, and the mechanism is the inability of truncated NPAS3 to heterodimerize with ARNT2, as confirmed by co-immunoprecipitation. Reporter gene transcriptional activity assays; co-immunoprecipitation with ARNT2; clinical exome sequencing database variants Scientific reports Medium 33758288
2021 NPAS3 aggregation into an insoluble form is a widespread phenomenon in human insular cortex (detected in 70% of samples), is not limited to the V304I mutation, and oxidative stress plays a larger mechanistic role than the V304I mutation in promoting aggregation in neuroblastoma cells. Insoluble fraction purification from postmortem human cortex; western blotting; oxidative stress induction in neuroblastoma cells; fractionation Journal of personalized medicine Medium 34834422
2012 miR-17 post-transcriptionally regulates NPAS3 by binding to the NPAS3 3' UTR, as demonstrated by luciferase reporter assays, contributing to the dissociation between declining NPAS3 mRNA and increasing NPAS3 protein during human postnatal cortical development. Luciferase reporter assays with NPAS3 3' UTR; western blotting; microarray and qRT-PCR in postmortem human brain tissue Schizophrenia bulletin Medium 22228753
2022 NPAS3 is a critical regulator of astrogenesis in the developing cortex; Npas3 knockout impairs the differentiation trajectory from radial glia to astrocytes (shown by single-cell transcriptomics). ChIP-seq in primary cortical astrocytes shows NPAS3 binds chromatin targets involved in brain development and synapse organization. Astrocyte-specific Npas3 knockdown causes synaptic and behavioral deficits, and NPAS3-impaired astrogenesis induces synaptic deficits in wild-type neurons in co-culture. Npas3 KO mouse; single-cell RNA-seq; ChIP-seq in primary cortical astrocytes; astrocyte-specific in vivo knockdown; neuron-astrocyte co-culture assay; behavioral testing Cell reports High 36044858
2022 Npas3 knockdown in cortical neural progenitor cells impairs neuronal radial migration, changes laminar cell fate, and promotes stemness maintenance and increased proliferation of radial glial cells in the VZ/SVZ, indicating that Npas3 regulates the transition from progenitor proliferation to neuronal differentiation and migration in the developing cerebral cortex. In utero knockdown of Npas3 in cortical VZ progenitors; histological and immunofluorescence analysis of cortical lamination and progenitor markers Frontiers in cellular neuroscience Medium 36313621
2023 A covalent compound (Compound 6) blocks NPAS3-ARNT heterodimer formation by covalently binding to ARNT Cys336, effectively down-regulating NPAS3 transcriptional function at the cellular level; this identifies ARNT Cys336 as the binding site and the 5-nitrothiazole-2-sulfydryl group as a cysteine-targeting warhead for disrupting the NPAS3-ARNT interface. Biochemical NPAS3-ARNT heterodimer formation assay (EC50 measurement); cellular transcriptional reporter assays; covalent inhibitor medicinal chemistry and structure-activity relationship Bioorganic chemistry Medium 37352720
2026 In astrocytes, AEBP1 sequesters NPAS3 in the cytoplasm, preventing its nuclear binding to the Lipa promoter; when AEBP1 is overexpressed, NPAS3 fails to activate LIPA transcription, leading to lipid droplet accumulation, excess cholesteryl ester storage, lysosomal Aβ retention, and worsened Alzheimer's pathology in 5×FAD mice. Astrocyte-specific AEBP1 knockdown/overexpression in 5×FAD mice; hippocampal transcriptomics and metabolomics; LIPA promoter binding assay; NPAS3 cytoplasmic sequestration demonstrated by protein localization; in vitro cultured astrocyte experiments Cell reports Medium 41880326
2020 NPAS3 functions as a direct target of miR-122 in endothelial cells; NPAS3 silencing abolishes the anti-EndMT (endothelial-to-mesenchymal transition) effect of miR-122 inhibition, placing NPAS3 downstream of miR-122 in the regulation of EndMT and atherosclerosis. miR-122 mimic/inhibitor transfection in endothelial cells; NPAS3 siRNA knockdown; western blotting for endothelial and mesenchymal markers; lenti-virus injection in ApoE-/- mice Life sciences Medium 33278397
2025 The lncRNA 3222401L13Rik mediates its effects on astrocyte neuronal-support gene expression through interaction with NPAS3; overexpression of NPAS3 rescues the functional deficits in astrocytes caused by 3222401L13Rik knockdown. lncRNA knockdown in primary astrocytes; NPAS3 overexpression rescue assay; interaction between lncRNA and NPAS3 demonstrated Non-coding RNA Low 39846680

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors. Proceedings of the National Academy of Sciences of the United States of America 144 15347806
2008 Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molecular psychiatry 114 18521090
2008 Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Molecular psychiatry 84 18317462
2013 The developmental brain gene NPAS3 contains the largest number of accelerated regulatory sequences in the human genome. Molecular biology and evolution 81 23408798
2016 NPAS1-ARNT and NPAS3-ARNT crystal structures implicate the bHLH-PAS family as multi-ligand binding transcription factors. eLife 69 27782878
2005 Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 68 15924306
2005 Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice. The European journal of neuroscience 63 16190882
1999 Characterization of npas3, a novel basic helix-loop-helix PAS gene expressed in the developing mouse nervous system. Mechanisms of development 55 10534623
2006 The NPAS3 gene--emerging evidence for a role in psychiatric illness. Annals of medicine 44 17008307
2010 Association of NPAS3 exonic variation with schizophrenia. Schizophrenia research 40 20466522
2011 Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3. Molecular psychiatry 36 21709683
2013 A fast-evolving human NPAS3 enhancer gained reporter expression in the developing forebrain of transgenic mice. Philosophical transactions of the Royal Society of London. Series B, Biological sciences 35 24218632
2020 Inhibition of miR-122 reduced atherosclerotic lesion formation by regulating NPAS3-mediated endothelial to mesenchymal transition. Life sciences 32 33278397
2012 Expression of NPAS3 in the human cortex and evidence of its posttranscriptional regulation by miR-17 during development, with implications for schizophrenia. Schizophrenia bulletin 31 22228753
2009 NPAS3 is a trachealess homolog critical for lung development and homeostasis. Proceedings of the National Academy of Sciences of the United States of America 27 19581591
2011 NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas. The American journal of pathology 26 21703424
2016 A Mutation in NPAS3 That Segregates with Schizophrenia in a Small Family Leads to Protein Aggregation. Molecular neuropsychiatry 22 27867938
2022 Npas3 deficiency impairs cortical astrogenesis and induces autistic-like behaviors. Cell reports 20 36044858
2011 Immunohistochemical analyses of NPAS3 expression in the developing human fetal brain. Anatomia, histologia, embryologia 16 21306425
2016 NPAS3 Regulates Transcription and Expression of VGF: Implications for Neurogenesis and Psychiatric Disorders. Frontiers in molecular neuroscience 14 27877109
2018 Molecular analysis of NPAS3 functional domains and variants. BMC molecular biology 12 30509165
2021 Molecular characterisation of rare loss-of-function NPAS3 and NPAS4 variants identified in individuals with neurodevelopmental disorders. Scientific reports 10 33758288
2021 Protein Aggregation of NPAS3, Implicated in Mental Illness, Is Not Limited to the V304I Mutation. Journal of personalized medicine 9 34834422
2022 Npas3 regulates stemness maintenance of radial glial cells and neuronal migration in the developing mouse cerebral cortex. Frontiers in cellular neuroscience 8 36313621
2025 LncRNA 3222401L13Rik Is Upregulated in Aging Astrocytes and Regulates Neuronal Support Function Through Interaction with Npas3. Non-coding RNA 6 39846680
2015 Lower NPAS3 expression during the later stages of abnormal lung development in rat congenital diaphragmatic hernia. Pediatric surgery international 5 25862168
2015 Cumulative role of rare and common putative functional genetic variants at NPAS3 in schizophrenia susceptibility. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 5 25982957
2013 Novel alternative splice variants of chicken NPAS3 are expressed in the developing central nervous system. Gene 5 23962688
2024 The Human Accelerated Region HAR202 Controls NPAS3 Expression in the Developing Forebrain Displaying Differential Enhancer Activity Between Modern and Archaic Human Sequences. Molecular biology and evolution 2 39241178
2023 Discovery of a highly potent NPAS3 heterodimer inhibitor by covalently modifying ARNT. Bioorganic chemistry 2 37352720
2023 SYMPTOM SEVERITY IN SCHIZOPHRENIA PATIENTS WITH NPAS3, DYSBINDIN-1 AND/OR TRIOBP PROTEIN PATHOLOGY IN THEIR BLOOD SERUM: A PANSS-BASED FOLLOW UP STUDY. Psychiatria Danubina 2 37480305
2014 NPAS3 variants in schizophrenia: a neuroimaging study. BMC medical genetics 2 24674381
2010 Isolation and Characterization of Chicken NPAS3. Experimental neurobiology 1 22110344
2026 Astrocytic AEBP1-NPAS3-LIPA pathway coordinates cholesterol homeostasis to regulate Alzheimer's pathology. Cell reports 0 41880326

Missed literature

Know a paper Affinage missed for NPAS3? Flag it for the maintainers and the community.

No submissions yet.